NEW YORK, January 08, 2022 (GLOBE NEWSWIRE) – WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021 inclusive (the “Class Period “), from February 8, 2022 principal applicant deadline.
SO WHAT: If you purchased securities of Revance during the Class Period, you may be entitled to compensation without payment of fees or direct costs under a contingency fee agreement.
WHAT TO DO NEXT: To join the Revance class action lawsuit, go to http://www.rosenlegal.com/cases-register-2179.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action. A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court no later than February 8, 2022. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies issuing opinions do not have significant experience, resources or recognition by their peers. Many of these companies do not actually litigate class actions in securities. Be wise in choosing a lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was appointed by law360 Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants throughout the litigation period made false and / or misleading statements and / or failed to disclose that: (1) quality control deficiencies existed in the Revance’s manufacturing facility for DaxibotulinumtoxinA for Injection (“DAXI”), the Company’s flagship drug candidate; (2) the aforementioned shortcomings reduced the likelihood that the United States Food and Drug Administration (“FDA”) would approve the DAXI Biologics (“BLA”) license application in its current form; (3) as a result, the DAXI BLA was unlikely to obtain FDA approval within the timeframe Revance advised investors; and (4) accordingly, the defendants’ public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.
To join the Revance class action lawsuit, go to http://www.rosenlegal.com/cases-register-2179.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action.
No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future payback does not depend on whether he is a principal applicant.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, New York 10016
Phone. : (212) 686-1060
Toll free: (866) 767-3653
Fax: (212) 202-3827